Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 298

1.

Second-generation vaccines against leishmaniasis.

Coler RN, Reed SG.

Trends Parasitol. 2005 May;21(5):244-9. Review.

PMID:
15837614
2.

Recent advances in vaccines for leishmaniasis.

Requena JM, Iborra S, Carrión J, Alonso C, Soto M.

Expert Opin Biol Ther. 2004 Sep;4(9):1505-17. Review.

PMID:
15335317
3.

Progress in vaccine research and possible effector mechanisms in visceral leishmaniasis.

Ravindran R, Ali N.

Curr Mol Med. 2004 Sep;4(6):697-709. Review.

PMID:
15357218
4.

Development of a leishmaniasis vaccine: the importance of MPL.

Reed SG, Coler RN, Campos-Neto A.

Expert Rev Vaccines. 2003 Apr;2(2):239-52. Review.

PMID:
12899575
5.

Vaccines in leishmaniasis: advances in the last five years.

Brodskyn C, de Oliveira CI, Barral A, Barral-Netto M.

Expert Rev Vaccines. 2003 Oct;2(5):705-17. Review.

PMID:
14711330
6.

Recombinant DNA-derived leishmania proteins: from the laboratory to the field.

Kubar J, Fragaki K.

Lancet Infect Dis. 2005 Feb;5(2):107-14. Review.

PMID:
15680780
7.

Vaccines for parasitic diseases.

Price VL, Kieny MP.

Curr Drug Targets Infect Disord. 2001 Nov;1(3):315-24. Review.

PMID:
12455404
8.

Immunity to Leishmania and the rational search for vaccines against canine leishmaniasis.

Reis AB, Giunchetti RC, Carrillo E, Martins-Filho OA, Moreno J.

Trends Parasitol. 2010 Jul;26(7):341-9. doi: 10.1016/j.pt.2010.04.005. Review.

PMID:
20488751
9.

Leishmania vaccines: progress and problems.

Kedzierski L, Zhu Y, Handman E.

Parasitology. 2006;133 Suppl:S87-112. Review.

PMID:
17274851
10.

Vaccines against leishmaniasis.

Modabber F.

Ann Trop Med Parasitol. 1995 Dec;89 Suppl 1:83-8. Review.

PMID:
8745930
11.

Live attenuated Leishmania vaccines: a potential strategic alternative.

Silvestre R, Cordeiro-da-Silva A, Ouaissi A.

Arch Immunol Ther Exp (Warsz). 2008 Mar-Apr;56(2):123-6. doi: 10.1007/s00005-008-0010-9. Review.

PMID:
18373245
12.

Leishmania donovani: identification of novel vaccine candidates using human reactive sera and cell lines.

Arora SK, Pal NS, Mujtaba S.

Exp Parasitol. 2005 Mar;109(3):163-70.

PMID:
15713447
13.

Vaccines for leishmaniasis: from proteome to vaccine candidates.

Schroeder J, Aebischer T.

Hum Vaccin. 2011 Jan-Feb;7 Suppl:10-5. Review.

PMID:
21245661
15.

Progress towards a Leishmania vaccine.

Tabbara KS.

Saudi Med J. 2006 Jul;27(7):942-50. Review.

PMID:
16830009
16.

Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.

Lemesre JL, Holzmuller P, Gonçalves RB, Bourdoiseau G, Hugnet C, Cavaleyra M, Papierok G.

Vaccine. 2007 May 22;25(21):4223-34.

PMID:
17395339
17.

Vaccination against Leishmania infections.

Mauël J.

Curr Drug Targets Immune Endocr Metabol Disord. 2002 Oct;2(3):201-26. Review.

PMID:
12476486
18.

Antigenicity of a whole parasite vaccine as promising candidate against canine leishmaniasis.

Giunchetti RC, Reis AB, da Silveira-Lemos D, Martins-Filho OA, Corrêa-Oliveira R, Bethony J, Vale AM, da Silva Quetz J, Bueno LL, França-Silva JC, Nascimento E, Mayrink W, Fujiwara RT.

Res Vet Sci. 2008 Aug;85(1):106-12.

PMID:
17950391
19.

Solution and solid-support synthesis of a potential leishmaniasis carbohydrate vaccine.

Hewitt MC, Seeberger PH.

J Org Chem. 2001 Jun 15;66(12):4233-43.

PMID:
11397159

Supplemental Content

Support Center